Keytruda (pembrolizumab)

pCPA File Number: 22099
Negotiation Status:
Under consideration for negotiation
Indication(s):
for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0292
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable